Allergic Rhinitis Due to PollenAllergic ConjunctivitisAllergic Asthma
Investigational drug(s) / intervention(s)
MATA trees or MATA grass
MATA trees or MATA grass: Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
Study summary
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.
Eligibility
Sex
ALL
Min age
5 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients from 5 years of age who are treated with TA Gräser top or TA Bäume top due to rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, which are caused by an IgE-mediated allergy to grass and rye pollen or birch, alder and hazel pollen according to the respective SmPC.
* Patients will only be included in this study after the decision on the treatment has been made.
Exclusion Criteria:
* History of allergen-specific immunotherapy (SIT) for trees or grass within the last 5 years
* If it´s intended to treat the patient with only a preseasonal therapy
* A patient should also not be included in the presence of any of the conditions listed in the respective SmPC
Primary outcome measure(s)
change in the combined symptom medication score (CSMS) — once a year for 5 years The primary endpoint is the change in the total combined symptom medication score (CSMS) during the entire study period, determined from the rhinoconjunctivitis daily symptom score (dSS) and rhinoconjunctivitis daily medication score (dMS), averaged over the respective peak pollen season
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
